Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 11/20 | 1.00 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.52 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
| ▸ | LAP3 | P28838 | 1/20 | 0.41 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.40 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.40 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1998330 | 1.00 | FOLH1 (1.00) | FOLH1NAALAD2ANPEPLAP3GABBR2 | |
| SCHEMBL1997642 | 1.00 | FOLH1 (1.00) | FOLH1NAALAD2ANPEPLAP3GABBR2 | |
| SCHEMBL14330735 | 1.00 | FOLH1 (1.00) | FOLH1NAALAD2ANPEPLAP3GABBR2 | |
| SCHEMBL14330756 | 1.00 | FOLH1 (1.00) | FOLH1NAALAD2ANPEPLAP3GABBR2 | |
| SCHEMBL2032825 | 1.00 | FOLH1 (1.00) | FOLH1NAALAD2ANPEPLAP3GABBR2 | |
| SCHEMBL14330734 | 1.00 | FOLH1 (1.00) | FOLH1NAALAD2ANPEPLAP3GABBR2 | |
| SCHEMBL2001657 | 1.00 | FOLH1 (1.00) | FOLH1NAALAD2ANPEPLAP3GABBR2 | |
| SCHEMBL14330757 | 1.00 | FOLH1 (1.00) | FOLH1NAALAD2ANPEPLAP3GABBR2 | |
| SCHEMBL2031866 | 1.00 | FOLH1 (1.00) | FOLH1NAALAD2ANPEPLAP3GABBR2 | |
| SCHEMBL14330758 | 1.00 | FOLH1 (1.00) | FOLH1NAALAD2ANPEPLAP3GABBR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110730908-B | Engineered cells expressing Prostate Specific Membrane Antigen (PSMA) or modified versions thereof and related methods | 朱诺治疗学股份有限公司 | 2025-01-21 | — | — | CN | claimed |
| CN-110730908-A | Engineered cells expressing Prostate Specific Membrane Antigen (PSMA) or modified forms thereof and related methods | 朱诺治疗学股份有限公司 | 2020-01-24 | — | — | CN | claimed |
| US-20120328518-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | PIRAMAL IMAGING SA (CH) | 2012-12-27 | — | — | US | claimed |
| EP-2513121-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | Piramal Imaging SA (CH) | 2012-10-24 | — | — | EP | claimed |
| EP-2338892-A1 | Prostate specific membrane antigen inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-06-29 | — | — | EP | claimed |
| WO-2011073286-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-23 | — | — | WO | claimed |
| CN-110730908-B | Engineered cells expressing Prostate Specific Membrane Antigen (PSMA) or modified versions thereof and related methods | 朱诺治疗学股份有限公司 | 2025-01-21 | — | — | CN | disclosed |
| CN-110730908-A | Engineered cells expressing Prostate Specific Membrane Antigen (PSMA) or modified forms thereof and related methods | 朱诺治疗学股份有限公司 | 2020-01-24 | — | — | CN | disclosed |
| US-20120328518-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | PIRAMAL IMAGING SA (CH) | 2012-12-27 | — | — | US | disclosed |
| US-20120328518-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | PIRAMAL IMAGING SA (CH) | 2012-12-27 | — | — | US | disclosed |
| US-20120328518-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | PIRAMAL IMAGING SA (CH) | 2012-12-27 | — | — | US | disclosed |
| EP-2513121-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | Piramal Imaging SA (CH) | 2012-10-24 | — | — | EP | disclosed |
| EP-2338892-A1 | Prostate specific membrane antigen inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-06-29 | — | — | EP | disclosed |
| EP-2338892-A1 | Prostate specific membrane antigen inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-06-29 | — | — | EP | disclosed |
| WO-2011073286-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011073286-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120328518-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | KLK3, FOLH1, ACP3 | FOLH1 2/4885NAALAD2 123/4885ANPEP 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.